Lead Product(s): Perillyl Alcohol
Therapeutic Area: Oncology Product Name: NEO100
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: NeOnc Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2021
As part of the partnership, Anova will support patient identification and access to NEO100 clinical trials, and when clinical trials are not an option for patients with IDH1 mutated Glioma, early access for compassionate use will be supported.